Fig. 6
From: Typing tumors using pathways selected by somatic evolution
Exploration and validation of mutated ESPs in multiple cancers. a Mutated ESP characteristic of liver cancer subtype 1/2. b Kaplan–Meier survival plot for the liver ESP shown in a on patients in TCGA (Methods). c Corresponding Kaplan–Meier survival plot for patients in ICGC. d Stratification of patients using the aggregate of genes in the liver ESP vs. each of its genes individually. e Difference in drug resistance based on status of the ESP shown in a (Methods). Drug resistance is assessed by log(IC50) of liver cell lines in the GDSC dataset. p-value is calculated using a one-sided Wilcoxon signed-rank test. Box plots show the median, the 25th and 75th percentiles. f Mutated ESP characteristic of lung cancer subtype 1/5. g Kaplan–Meier survival plot for the lung ESP shown in f on patients in TCGA (Methods). h Corresponding Kaplan–Meier survival plot for patients in MSK-IMPACT. i Stratification of patients using the aggregate of genes in the lung ESP vs. each of its genes individually. j Difference in drug resistance based on status of the ESP shown in f (Methods). Drug resistance and p-value are calculated the same as for (e)
